Document is current
Any future updates will be listed below
-
Authors
Tanaka, Yoshiya https://orcid.org/0000-0002-0807-7139
Westhovens, Rene https://orcid.org/0000-0002-3432-3073
Sun, Hong
Van der Donckt, Carole https://orcid.org/0009-0007-5463-4315
Zhong, Yan
Kaise, Toshihiko https://orcid.org/0000-0001-6059-7900
-
Funding
Funding for this research was provided by:
Gilead Sciences K.K., Tokyo, Japan
Boehringer Ingelheim Japan
- License Information
-
More Information
Article History
Received: 12 November 2024
Accepted: 7 March 2025
First Online: 10 April 2025
Declarations
:
: Yoshiya Tanaka received speaking fees and/or honoraria from AbbVie; Asahi Kasei; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Chugai Pharmaceutical; Daiichi Sankyo; Eisai; Eli Lilly; Gilead Sciences, Inc.; GSK; Pfizer; Taisho Pharmaceutical; and UCB and received research grants from Boehringer Ingelheim, Chugai Pharmaceutical, and Taisho Pharmaceutical. Yoshiya Tanaka is an Editorial Board member of Rheumatology and Therapy. Yoshiya Tanaka was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Rene Westhovens acted as an adviser and speaker for Celltrion, Galapagos, and Gilead Sciences, Inc. Hong Sun is an employee of Medataccess. Carole Van der Donckt is an employee of Alfasigma S.p.A. Yan Zhong is an employee and shareholder of Gilead Sciences, Inc. Toshihiko Kaise is an employee of Gilead Sciences K.K., Tokyo, Japan, and a shareholder of Gilead Sciences, Inc.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. All studies were previously published, and no informed consent was necessary or obtained for inclusion in this meta-analysis. Readers are invited to refer to each trial publication for the relevant ethics disclosure.
